Sanofi (SNY.US) Consumer Health Department's battle is heating up, with lenders preparing over 10 billion euros in funds to support the acquisition.
Some core banks have signed financing commitments for priority debt of 7.5 billion to 7.8 billion euros over the weekend to support the bid for this acquisition. They will also provide a revolving credit line of approximately 1.2 billion euros.
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Sanofi:la Presidencia Polaca De La UE Allana El Camino Para Una Industria Farmacéutica Competitiva
Express News | I-mab and Sanofi have reached an authorization agreement, with a potential total price of up to 0.2 billion euros.
Sanofi's Market Advantage and Growth Trajectory: A Strong Buy Recommendation
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Cardinal Health (CAH) and Sanofi (OtherSNYNF)
Sanofi's Tolebrutinib Delays MS Disability Progression
Market Chatter: Sanofi Consumer Health Division Attracts Bids From 2 Private Equity Firms
Sanofi Gets Binding Bids for Consumer Unit: Bloomberg News
Express News | Sanofi received two quotes, with its consumer health department valued at approximately $17 billion.
Sector Update: Health Care Stocks Decline Tuesday Afternoon
Sector Update: Health Care
'Sanofi Gets Binding Bids From CD&R, PAI for Consumer Arm' - Bloomberg
Lenders Commit Over $11 Billion for Buyout of Sanofi Consumer Health Unit, Bloomberg Reports
Express News | Market news: Loan institutions are preparing to provide over 10 billion euros in funding to support the acquisition of Sanofi's health division (SNY.O).
Lenders Line Up Over €10 Billion for Sanofi Health Unit Buyout
Sanofi's Promising Portfolio Drives Buy Rating Amid MS, Cancer Breakthroughs, and Vaccine Expansion
The CEO of Sanofi believes that the company is expected to achieve growth through a variety of new drugs.
According to Reuters on September 24th, Sanofi's CEO Paul Hudson said in an interview on Monday that the company is expected to achieve strong growth through a variety of new drugs, and will not face the issue of best-selling products expiring and high costs like some competitors. The company has 12 potential blockbuster assets in the fields of immunology and vaccines, with no significant patents expiring before the end of this century. The company has not yet entered the lucrative obesity drug market. Hudson said that Sanofi does not want to create drugs like Ozempic or Mounjaro, both GLP-1 drugs.
Sanofi Gains Exclusivity Rights to Ventyx's CNS-penetrant Drug in $27m Deal